PhotoCure ASA has scheduled financial events as follows for 2001:
14.02.2001 - Financial Accounts 2000
29.03.2001 - General Meeting
09.05.2001 - Report 1st Quarter 2001
22.08.2001 - Report 2nd Quarter 2001
07.11.2001 - Report 3rd Quarter 2001
PhotoCure ASA is a Norwegian listed company founded in 1993. PhotoCure ASA's mission is to develop and sell pharmaceuticals and medical devices based on proprietary photodynamic technologies. The company is developing products for skin cancer and other skin diseases, internal cancer, gene therapy and cancer vaccines. PhotoCure has filed two applications for European marketing approval for its first pharmaceutical product, Metvix®, for treatment of non-melanoma skin cancer (Basal cell carcinoma not suitable for traditional therapy) and pre-cancerous skin lesions (actinic keratosis) respectively. Hexvix®, PhotoCure's second pharmaceutical product, is currently in clinical phase II for photo detection of bladder cancer.
Oslo 2nd of February 2001.
For more information contact:
PhotoCure ASA
Attn. Vidar Hansson, CEO
Hoffsveien 48
0377 Oslo
Norway